Systemic administration of peptides for treatment of spinal cord injury and/or remyelination

A spinal cord injury, systemic technology for systemic administration of peptides for the treatment of spinal cord injury and/or remyelination, capable of addressing issues such as low permeability, low bioavailability, and short half-life

Pending Publication Date: 2022-05-27
AXOLTIS PHARMA
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

One of the major limitations of therapeutic peptides is their short half-life, resulting in low bioavailability
Another important issue in the case of the development of therap...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Systemic administration of peptides for treatment of spinal cord injury and/or remyelination
  • Systemic administration of peptides for treatment of spinal cord injury and/or remyelination
  • Systemic administration of peptides for treatment of spinal cord injury and/or remyelination

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] "SCO-spondin" is a central nervous system-specific glycoprotein found in all vertebrates from prechordates to humans. It's called an extracellular matrix molecule, and it's secreted by a specific organ located on top of the third ventricle (the subcommissural organ). It is a large size molecule. It consists of more than 4,500 amino acids and has a multi-module organization that includes various retained protein patterns, in particular including 26 TR or TSR patterns. Certain SCO-spondin-derived peptides starting from the TSR pattern are known to be biologically active in nerves or neural cells (described in particular in WO-99 / 03890).

[0020] A "TSR or TR pattern" is a protein domain of approximately 55-60 residues based on an alignment of the retained amino acids cysteine, tryptophan, and arginine. These patterns were first isolated in TSP-1 (thrombospondin 1), a molecule that interferes with blood clotting. They were then described in many other molecules such as ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the treatment of non-cranial nervous system injury, such as spinal cord injury and/or optic nerve injury, with an SCO-Spondin-derived peptide administered to a patient by systemic route. The present invention relates to a peptide having the amino acid sequence X1-W-S-A1-W-S-A2-C-S-A3-A4-C-G-X2 wherein A1, A2, A3 and A4 consist of an amino acid sequence consisting of 1 to 5 amino acids and X1 and X2 consist of an amino acid sequence consisting of 1 to 6 amino acids; or X1 and X2 are absent; the N-terminal amino acid can be acetylated, the C-terminal amino acid can be amidated, or the N-terminal amino acid can be acetylated and the C-terminal amino acid can be amidated. The use of such peptides for remyelination is also described.

Description

technical field [0001] The present invention relates to systemic administration of SCO-Spondin derived peptides to treat non-cerebral nervous system injuries, such as spinal cord injury and / or optic nerve injury. It also involves systemic administration of SCO-Spondin derived peptides for remyelination in myelopathy, including spinal cord injury and other forms of myelopathy associated with the spinal cord or central nervous system. Background technique [0002] Spinal cord injury (SCI) results in a high incidence of incomplete / complete sensorimotor paralysis. Primary injury results in necrosis and hemorrhage, followed by secondary injury, including gliosis. [0003] Traumatic optic nerve injury is the leading cause of irreversible blindness worldwide and leads to progressive visual impairment. To date, neither medical nor surgical intervention has been sufficient to stop or reverse the progression of vision loss. Axon regeneration is critical for functional recovery of v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/47A61K38/17A61P25/00
CPCC07K14/47A61K38/1709A61P25/00A61K38/10C07K7/08A61P25/28A61K38/00
Inventor Y·戈德弗瑞恩M·布兰克
Owner AXOLTIS PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap